Lack of Association between Sputum Atypia and Chronic Obstructive Pulmonary Disease Mortality  by Miller, York E. et al.
ORIGINAL ARTICLE
Lack of Association between Sputum Atypia and Chronic
Obstructive Pulmonary Disease Mortality
York E. Miller, MD,*†‡ Kieu O. Vu, MS,§ Tim C. Kennedy, MD,†‡
Fred R. Hirsch, MD, PhD,†‡¶ Thomas L. Petty, MD,†‡ Paul A. Bunn, Jr., MD,†‡
Robert L. Keith, MD,*†‡ Wilbur A, Franklin MD,†¶ Holly J. Wolf, PhD,†
Sheila Prindiville, MD,# and Tim Byers, MD†
Hypothesis: Chronic obstructive pulmonary disease (COPD) and
lung cancer are thought to share common elements in pathogenesis.
The authors hypothesized that sputum atypia would reflect the
processes leading to progressive airflow obstruction and might be a
novel biomarker of more rapidly progressive COPD.
Methods: The authors analyzed the association between COPD
death and sputum cytologic atypia in an ongoing cohort of 2013
smokers with varying degrees of airflow obstruction during the
period between January 1, 1993, and July 1, 2001.
Results: There were 326 deaths attributed to COPD over 4495 person-
years, giving a COPD death rate of 7.25 deaths per 100 person-years,
which is highly elevated compared with fewer than 0.2 COPD deaths
per 100 person-years for the United States population aged between 65
and 74 years. Sputum atypia was not associated with either the degree
of airflow obstruction or death from COPD. COPD death was associ-
ated with age and degree of airflow obstruction, as expected.
Conclusion: Sputum cytologic atypia is not predictive of death from
COPD. As sputum cytologic grades of moderate or worse atypia are
associated with a significant increase in the risk for lung cancer and do
not denote a group with increased competing death rates from COPD,
patients with sputum atypia are a good high risk group in whom
chemoprevention and early detection studies can be conducted.
Key Words: Lung cancer, Sputum cytology, Airflow obstruction,
Chronic obstructive pulmonary disease, Bronchial epithelium.
(J Thorac Oncol. 2006;1: 302–307)
Tobacco smoking results in airway and alveolar inflamma-tion in all individuals.1 However, only a subset of 15 to
25% of smokers develop clinically apparent airflow obstruc-
tion.2 These individuals can be identified before the onset of
clinical symptoms related to airflow obstruction by an accel-
erated rate of loss of forced expiratory volume in 1 second
(FEV1) on simple spirometry.3 Several studies have demon-
strated that individuals with chronic obstructive pulmonary
disease are at increased risk for the development of lung
cancer, compared with smokers with a similar tobacco smoke
exposure but no airflow obstruction on pulmonary function
testing.4–6 A recently published small case-control study
suggests that airflow obstruction is primarily a risk factor for
squamous cell lung cancer, whereas a history of chronic
bronchitis is a risk factor for adenocarcinoma of the lung.7
The reason for the association between airflow obstruc-
tion and lung cancer is not known. A common genetic
susceptibility to chronic obstructive pulmonary disease and
lung cancer is one possible mechanism.8 Cohen et al. reported
in 1977 that first-degree relatives of lung cancer patients and
patients with chronic obstructive pulmonary disease had
lower smoking-, age-, and sex-adjusted FEV1 measurements
than controls, suggesting that lung cancer and chronic ob-
structive pulmonary disease share a common familial com-
ponent other than smoking.9 Genetically determined variation
in inflammation, oxidative stress, or antioxidant defenses are
attractive mechanisms for the shared susceptibility to lung
cancer and chronic obstructive pulmonary disease (COPD);
however, there have been few data to support these hypoth-
eses.10
Increased thickness of the airway wall and loss of
elastic recoil from the alveolar destruction present in emphy-
sema are two contributory mechanisms for the decreased
airflow that defines COPD.11 In a recent analysis of the
morphometric correlates of airflow obstruction, thickness of
the small airway walls was more highly correlated with
airflow obstruction than was airway inflammation or emphy-
sema.12 All three components (epithelium, lamina propria,
and adventitia) of the airway wall were correlated with
airflow obstruction, but the epithelial thickness was the most
highly correlated. Bronchial epithelial dysplasias are often
characterized by epithelial hypercellularity and increased ep-
ithelial thickness.13 Therefore, we hypothesized that sputum
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atypia would be a biomarker of accelerated airflow loss and
would be correlated with an increased death rate caused by
COPD.
PATIENTS AND METHODS
The University of Colorado Cancer Center Sputum
Screening Cohort Study is an ongoing prospective study
initiated in 1993 to determine whether sputum cytologic
atypia or other sputum, urine, or serum biomarkers predict the
development of lung cancer.14 The cohort composition, re-
cruitment methods, and inclusion criteria have been described
previously, and a report describing the relationship between
personal and behavioral characteristics, pulmonary function,
sputum cytologic atypia, and development of lung cancer was
recently published.15 Briefly, subjects have been recruited
mainly from community and academic pulmonary clinics in
the Denver, Colorado, area. Subjects were older than 25
years, had a cigarette smoking history of 30 pack-years or
more, and demonstrated airflow obstruction, defined as FEV1
less than 75% predicted for age, race, gender, height, and
weight and an FEV1/forced vital capacity ratio of less than
0.75 on spirometry. Exclusions included a diagnosis of cancer
(except for nonmelanoma skin cancer) within 5 years before
recruitment, a current acute respiratory infection, or a life
expectancy judged to be less than 5 years by the patient’s
physician.
As previously described, 2550 subjects were enrolled
into the cohort as of July 1, 2001; of these, 537 did not submit
a sputum specimen for analysis. Details of sputum collection,
processing, and interpretation have been described recently.
Sputum cytologic diagnoses were divided into five groups:
unreadable specimen containing no informative bronchial
epithelial cells; normal or squamous metaplasia; mild atypia;
moderate atypia; or worse than moderate atypia (severe
atypia or carcinoma). Cohort follow-up was accomplished by
both active (mailings and telephone interviews) and passive
means, including matching to the Colorado Department of
Vital Statistics records (through June 1, 2001) and the Na-
tional Death Index (through December 31, 1999) to deter-
mine the date and cause of death, and the Colorado Central
Cancer Registry for lung cancer diagnosis. There were 721
documented deaths in the cohort between January 1, 1993,
and June 1, 2001.
Statistical Analysis
Each potential risk factor for COPD death was exam-
ined first by univariate categorical analysis and then by
proportional hazards regression analysis.16 The proportional
hazards regression analyses were conducted in three stages—
first, using crude models for the association between sputum
atypia and COPD death; second, using multivariate models,
adjusting for the potential confounding factors of age, sex,
race, and year of enrollment into the cohort; and third, in full
models that also added smoking status and pack-years of
smoking history at enrollment. Smoking status at enrollment
was defined as current or former smoking, with former
smoking defined as having stopped all smoking for 1 year or
more. Pack-years of cigarette smoking at enrollment was
defined as the average number of packs smoked per day
multiplied by the number of years of smoking. Cohort mem-
bers were included in the analysis from the age at the first
sputum sample, and then censored at the time of their death,
lung cancer incidence, or the last date of contact if lost to
follow-up as of December 31, 2001 (the close of the cohort
follow-up period for this analysis). Two sets of regression
models were run—one using the baseline sputum sample and
one in which the baseline sample and up to five subsequent
sputum samples (the maximum number obtained from any
case) was examined using a time-varying covariate analysis
of the repeated measures of sputum cytology.16 The fre-
quency relationship between sputum cytology grade and
death from all causes, heart disease, pneumonia, and influ-
enza was also assessed. All analyses were carried out using
SAS, Version 8.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Patient characteristics have been recently published,
but in brief, the cohort was predominantly male (70%),
Caucasian (93%), and elderly (79% aged 60 years or older).15
Most (59%) were former smokers as opposed to current
smokers, and the smoking history was heavy, with 54%
reporting more than 55 pack-years of tobacco use. Sputum
cytologic dysplasia was frequent, with 17.8% demonstrating
moderate atypia or worse at baseline examination (Table 1).
There was no association between percentage predicted FEV1
and sputum cytologic atypia (Table 1).
There were 326 deaths attributed to COPD in the study
period, comprising 4495 person-years, resulting in a COPD
death rate of 7.25 deaths per 100 person-years. The death rate
from COPD in the United States population aged 65 to 74 is
less than 0.2 per 100 person-years (calculated using the
Centers for Disease Control and Prevention WONDER web-
site: http://wonder.cdc.gov). It is not unexpected for a popu-
lation recruited based on the definition of COPD that the
COPD death rate would be elevated. The relationship be-
tween patient characteristics and COPD death was examined
(Table 2). There was no relationship between gender or race
and COPD death rate. Increasing age correlated with in-
creased risk of COPD death (COPD death rate per 100
patient-years for ages 30–59, 60–69, and 70 years of 4.33,
6.04, and 10.03, respectively; p trend  0.0001). The subjects
recruited in the first 4 years of the cohort study had a higher
COPD death rate than those in the last 4 years (7.86 versus
4.93; p  0.0001), and those within the lowest quartile of
lifetime smoking history had a modest reduction in COPD
death rate (Table 2). As expected, percentage predicted FEV1
was strongly correlated with COPD death rate, with those in
the lowest quartile of FEV1 having a relative risk of COPD
death of 5.8 compared with those in the upper quartile (p trend
 0.0001). The lack of chronic bronchitis as defined by a
productive cough for 3 months or more per year during the
past 2 years also correlated with a decreased risk of COPD
death (relative risk, 0.45; p  0.02).
The relationship between sputum cytologic results and
COPD death rate was analyzed. Unexpectedly, there was no
increase in COPD death rate with increasing level of sputum
cytologic atypia in the univariate model (Table 2). Several
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multivariate models were then applied, adjusting for (1) age,
gender, race, and recruitment year; (2) age, gender, race,
recruitment year, and percentage predicted FEV1; (3) age,
gender, race, recruitment year, pack-years, and smoking sta-
tus; and (4) age, gender, recruitment year, pack-years, per-
centage predicted FEV1, and smoking status. In none of these
analyses was there a relationship between moderate or greater
sputum cytologic atypia, either in the initial baseline sputum
or in the first six sputum samples, and COPD death rate
(Table 3). In addition, there was no relationship between
sputum cytologic atypia and death from all causes, heart
disease, or pneumonia and influenza.
TABLE 1. Characteristics of Cohort Members and Association between Selected Factors and Cytologic Finding from the
Baseline Sputum Sample, from the University of Colorado Lung Cancer SPORE Cohort, 1993 to June 2001
Cohort Characteristics
Baseline Sputum Cytologic Reading
Unreadable
Normal or
Squamous
Metaplasia
Mild
Atypia
Moderate
Atypia
Worse Than
Moderate
Atypia
Moderate or
Worse Atypia
No. % No. % No. % No. % No. % No. % No. %
Total cohort 2013 100 234 11.6 439 21.8 982 48.8 323 16.1 35 1.7 358 17.8
Gender
Female 600 29.8 82 13.7 139 23.2 291 48.5 82 13.7 6 1.0 88 14.7
Male 1413 70.2 152 10.8 300 21.2 691 48.9 241 17.1 29 2.1 270 19.1
p  0.02
Age
30–59 yr 425 21.1 36 8.8 86 20.2 221 52.0 75 17.7 7 1.7 82 19.3
60–69 yr 798 39.6 88 11.0 182 22.8 392 49.1 122 15.3 14 1.8 136 17.0
70 yr 790 39.2 110 13.9 171 21.7 369 46.7 126 16.0 14 1.8 140 17.7
p  NS
Race
Caucasian 1873 93.1 215 11.5 419 22.4 912 48.7 298 15.9 29 1.6 327 17.5
Hispanic 62 3.1 8 12.9 6 9.7 21 50.0 15 24.2 2 3.2 17 27.4
African American 53 2.6 7 13.2 9 17.0 23 43.4 10 18.9 4 7.6 14 26.4
Asian, Native American, other 25 1.2 4 16.0 5 20.0 16 64.0 0 0 0 0 0 0
p  0.01
Recruitment year
January 1, 1993–June 30, 1997 1135 56.4 180 15.9 194 17.1 507 44.7 232 20.4 22 1.9 254 22.4
July 1, 1997–June 30, 2001 878 43.6 54 6.2 245 27.9 475 54.1 91 10.4 13 1.5 104 11.9
Smoking status
Current smoker 824 40.9 70 8.5 155 18.8 429 52.1 151 18.6 19 2.3 170 20.6
Former smoker 1189 59.1 164 13.8 284 23.9 553 46.5 172 14.5 16 1.4 188 15.8
p  0.01
Lifetime smoking history
Quartile 1, 43 pack-years 448 22.3 47 10.5 99 22.1 235 52.5 61 13.6 6 1.4 67 15.0
Quartile 2, 43–54 pack-years 478 23.8 60 12.6 102 21.3 216 45.2 88 18.4 12 2.5 100 20.9
Quartile 3, 55–80 pack-years 594 29.5 70 11.8 133 22.4 289 48.7 96 16.2 6 1.0 102 17.2
Quartile 4,  81 pack-years 493 24.5 57 11.6 105 21.3 242 49.1 78 15.8 11 2.2 89 18.1
p  NS
Percentage predicted FEV1
Quartile 1 (30%) 580 28.9 71 12.2 133 22.9 286 49.3 81 14.0 9 1.6 90 15.5
Quartile 2 (30–42%) 4\557 27.8 81 14.5 118 21.2 251 45.1 98 17.6 9 1.6 107 19.2
Quartile 3 (43-54%) 449 21.0 42 10.0 82 19.5 220 52.3 69 16.4 8 1.9 77 18.3
Quartile 4 ( 55%) 421 21.0 42 10.0 82 19.5 220 52.3 69 16.4 8 1.9 77 18.3
p  NS
Have you coughed up mucus daily
for 3 or more months per
year during the past 2 years?
Yes 805 75.9 52 6.5 208 25.8 408 50.7 124 15.4 13 1.6 137 17.0
No 255 24.1 26 10.2 61 23.9 139 54.5 26 10.2 3 1.2 29 11.4
p  0.05
NS, not significant.
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DISCUSSION
COPD and lung cancer are likely to share common, but
incompletely understood, elements in pathogenesis. The
thickness of epithelium in the small airways of smokers is the
best morphometric correlate of airflow obstruction.12,17 Bron-
chial epithelial dysplasias are hyperproliferative lesions and
often exhibit epithelial hypercellularity.13 We hypothesized
that sputum cytologic dysplasia would be a biomarker denot-
TABLE 2. COPD Deaths as Related to Selected Factors in the University of Colorado Lung Cancer SPORE Cohort, 1993–2001
Person-Years
COPD Death
Cases
COPD Death Rateper
100 Person-Years
(95% CI)
Incidence Rate Ratio
(95% CI)
Total cohort 4495.03 326 7.25 (6.47–8.04)
Gender
Female 1233.60 102 8.27 (6.66–9.87) Reference (1.0)
Male 3261.20 224 6.87 (5.97–7.77) 0.83 (0.66–1.05)
p  NS
Age
30–59 yr 877.20 38 4.33 (2.95–5.71) Reference (1.0)
60–69 yr 1872.11 113 6.04 (4.92–7.15) 1.39 (0.96–2.01)
70 yr 1745.11 175 10.03 (8.54–11.51) 2.31 (1.63–3.29)
ptrend  0.0001
Race
Caucasian 4219.87 312 7.39 (6.57–8.21) Reference (1.0)
Hispanic 120.40 4 3.32 (0.66–6.58) 0.45 (0.17–1.20)
African American 113.58 7 6.16 (1.60–10.73) 0.83 (0.39–1.76)
Asian, Native American, other 40.56 3 7.40 (–0.97–15.77) 1.00 (0.32–3.12)
Year of recruitment
January 1, 1993, to June 30, 1997 3561.63 280 7.86 (6.94–8.78) Reference (1.0)
July 1, 1997, to June 30, 2001 933.31 46 4.93 (3.50–6.35) 0.63 (0.46–0.86)
Smoking status
Current smoker 1815.27 114 6.28 (5.13–7.43) 0.79 (0.63–1.00)
Former smoker 2678.82 212 7.91 (6.85–8.98) Reference (1.0)
p  0.016
Lifetime smoking history
Quartile 1, 43 pack-years 879.87 49 5.57 (4.01–7.13) Reference (1.0)
Quartile 2, 43–54 pack-years 1075.98 79 7.34 (5.72–8.96) 1.32 (0.92–1.88)
Quartile 3, 55–80 pack-years 1358.48 111 8.17 (6.65–9.69) 1.47 (1.05–2.05)
Quartile 4, 81 pack-years 1180.24 87 7.37 (5.82–8.92) 1.32 (0.96–1.88)
ptrend 0.005
Percentage predicted FEV1
Quartile 1 (30%) 1237.14 174 14.06 (11.97–16.15) Reference (1.0)
Quartile 2 (30–42%) 1377.46 95 6.90 (5.51–8.28) 0.49 (0.38–0.63)
Quartile 3 (43–54%) 911.02 34 3.73 (2.48–4.99) 0.27 (0.18–0.38)
Quartile 4 (55%) 949.78 23 2.42 (1.43–3.41) 0.17 (0.11–0.27)
ptrend  0.0001
Have you coughed up mucus daily
for 3 or more months per year
during the past 2 years?
Yes 1658.30 57 3.44 (2.54–4.33) Reference (1.0)
No 512.04 8 1.56 (0.48–2.65) 0.45 (0.22–0.95)
p  0.022
Baseline sputum cytology
Unreadable 618.23 57 9.22 (6.83–11.61) 1.44 (1.00–2.09)
Normal 861.76 55 6.38 (4.70–8.07) Reference (1.0)
Mild atypia 2066.13 147 7.11 (5.96–8.26) 1.11 (0.82–1.52)
Moderate atypia 869.84 65 7.47 (5.66–9.29) 1.17 (0.26–4.80)
Worse than moderate atypia 78.61 2 2.54 (–0.98–6.07) 0.40 (0.10–1.63)
ptrend  NS
Moderate atypia or worse 948.70 67 7.06 (5.37–8.75) 1.11 (0.77–1.58)
ptrend  NS
NS, not significant.
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ing poor prognosis in terms of COPD outcome. In the
University of Colorado Cancer Center Sputum Screening
Cohort Study, we have enrolled 2550 patients with airflow
obstruction, analyzed baseline and serial sputum cytology
and obtained information on deaths from COPD; 17.8% of
these subjects had moderate atypia or worse on initial sputum
cytology. Three hundred twenty-six deaths from COPD were
identified.
As expected, advanced age and diminished percentage
predicted FEV1 correlated strongly with COPD death rate.
There was a positive correlation between increased tobacco
smoke exposure in pack-years and COPD death. Former
smokers exhibited a small increase in COPD death rate; this
may have been the result of increased symptomatology lead-
ing to smoking cessation. The symptom of chronic bronchitis
was also associated with an approximately twofold increase
in COPD death rate.
Unexpectedly, we found no evidence of a relationship
between sputum cytologic dysplasia and death rate from
COPD, on either univariate or multivariate analysis. Further-
more, there was no correlation between degree of airflow
obstruction and sputum cytologic dysplasia. This could mean
that dysplastic bronchial epithelium does not make a signif-
icant contribution to airflow obstruction. As dysplastic le-
sions are localized rather than diffuse, it is likely that they do
not affect a large enough fraction of the airway epithelium to
create airflow obstruction. Furthermore, our results suggest
that the presence of bronchial epithelial dysplasia may not be
associated with diffuse thickening of the airway epithelium.
The relative contributions of airway wall thickness and loss
of elastic recoil secondary to emphysema-associated alveolar
wall destruction are not known; thus, emphysema, rather than
increased airway wall thickness, may be a more critical factor
in the progression of COPD to death. To the extent that
sputum cytologic dysplasia may reflect susceptibility to bron-
chial epithelial cell damage from inflammation and oxidants
and carcinogens present in cigarette smoke, it is somewhat
surprising that we found no association with poor outcome
from COPD.
There are limitations to the present study. All members
of the cohort have some degree of airflow obstruction. Thus,
the present study would not be able to detect an association
between airflow obstruction and sputum cytologic dysplasia
if a small degree of airflow obstruction is associated with
dysplasia, but no dose-response effect is present. We have
previously commented on the high incidence of sputum
cytologic dysplasia in the Colorado Cancer Center Sputum
Screening Cohort compared with other historical cohorts in
which airflow obstruction was not an inclusion criterion.14
Further studies are needed to determine whether there is a
threshold effect in the relationship between airflow obstruc-
tion and sputum cytologic atypia. Pulmonary function was
not measured serially in our cohort. This would have been a
more direct and sensitive reflection of COPD progression
than COPD death rates.
Finally, lung cancer risk has been demonstrated to
increase with increasing levels of sputum cytologic dysplasia,
particularly at levels of moderate atypia or worse.15,18,19 Thus,
individuals with moderate or greater sputum cytologic atypia
are a logical high-risk population in which to conduct che-
moprevention or screening studies. However, if sputum
atypia were a biomarker of poor prognosis from COPD, the
rationale for these preventive studies in that population would
be weakened because of a potential for overdiagnosis bias,
whereby subjects would die as a result of COPD rather than
lung cancer. We found no evidence that sputum atypia de-
TABLE 3. Association between Moderate or Greater Atypia in Sputum Samples and COPD Deaths
in the University of Colorado Lung Cancer SPORE Cohort, 1993–2001
Hazard Ratio* (95% CI)
Crude Model
Adjusted for Age, Sex,
Race, Recruitment Year
Adjusted for Age, Sex,
Recruitment Year,
Pack-Years, FEV1,
and Smoking Status
Initial baseline sputum
Unreadable 1.31 (0.90–1.90) 1.28 (0.88–1.86) 1.36 (0.93–1.98)
Normal 1.00 (reference) 1.00 (reference) 1.00 (reference)
Mild atypia 1.16 (0.85–1.59) 1.21 (0.89–1.66) 1.27 (0.93–1.74)
Moderate atypia 1.15 (0.80–1.65) 1.19 (0.83–1.71) 1.29 (0.89–1.85)
Worse than moderate atypia 0.42 (0.10–1.70) 0.46 (0.11–1.88) 0.42 (0.10–1.72)
Moderate atypia or worse 1.09 (0.76–1.56) 1.14 (0.79–1.63) 1.21 (0.84–1.74)
First six sputum samples
Unreadable 1.33 (0.92–1.92) 1.26 (0.87–1.83) 1.25 (0.87, 1.83)
Normal 1.00 (reference) 1.00 (reference) 1.00 (reference)
Mild atypia 0.95 (0.71–1.28) 0.97 (0.73–1.31) 1.01 (0.75–1.35)
Moderate atypia 0.99 (0.69–1.42) 1.01 (0.70–1.44) 1.06 (0.73–1.52)
Worse than moderate atypia 1.18 (0.47–2.94) 1.26 (0.51–3.15) 1.19 (0.48–3.00)
Moderate atypia or worse 1.00 (0.71–1.42) 1.02 (0.72–1.46) 1.07 (0.75–1.52)
*Hazard ratio, as estimated from proportional hazards analysis.
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notes a population in which competing deaths from COPD
diminish the rationale for chemoprevention or screening stud-
ies. As airflow obstruction, but not sputum atypia, is strongly
related to COPD death rates, the use of spirometric thresholds
to select subjects for screening and chemoprevention studies
may be useful.
CONCLUSION
Sputum cytologic atypia is not associated with an
increase in death rate from COPD. As sputum cytologic
grades of moderate or worse atypia are associated with a
significant increase in the risk for lung cancer and do not
denote a group with increased competing death rates from
COPD, patients with sputum atypia are a good high-risk
group in which chemoprevention and early detection studies
can be carried out.
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